|
Name |
Asporyzin C
|
Molecular Formula | C28H39NO2 | |
IUPAC Name* |
(1S,12S,15R,16S,17S,20S)-16-[(E)-4-hydroxy-4-methylpent-2-enyl]-1,16,20-trimethyl-3-azapentacyclo[10.8.0.02,10.04,9.015,20]icosa-2(10),4,6,8-tetraen-17-ol
|
|
SMILES |
C[C@]12CC[C@@H]([C@@]([C@@H]1CC[C@@H]3[C@@]2(C4=C(C3)C5=CC=CC=C5N4)C)(C)C/C=C/C(C)(C)O)O
|
|
InChI |
InChI=1S/C28H39NO2/c1-25(2,31)14-8-15-26(3)22-12-11-18-17-20-19-9-6-7-10-21(19)29-24(20)28(18,5)27(22,4)16-13-23(26)30/h6-10,14,18,22-23,29-31H,11-13,15-17H2,1-5H3/b14-8+/t18-,22-,23-,26-,27-,28+/m0/s1
|
|
InChIKey |
UCZDOMMSHDUFIK-TWQPBVKTSA-N
|
|
Synonyms |
Asporyzin C; CHEMBL1258978; J3.637.464K
|
|
CAS | NA | |
PubChem CID | 46945861 | |
ChEMBL ID | CHEMBL1258978 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 421.6 | ALogp: | 5.9 |
HBD: | 3 | HBA: | 2 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 56.2 | Aromatic Rings: | 5 |
Heavy Atoms: | 31 | QED Weighted: | 0.534 |
Caco-2 Permeability: | -4.856 | MDCK Permeability: | 0.00002710 |
Pgp-inhibitor: | 0.978 | Pgp-substrate: | 0.343 |
Human Intestinal Absorption (HIA): | 0.005 | 20% Bioavailability (F20%): | 0.375 |
30% Bioavailability (F30%): | 0.903 |
Blood-Brain-Barrier Penetration (BBB): | 0.424 | Plasma Protein Binding (PPB): | 98.49% |
Volume Distribution (VD): | 0.778 | Fu: | 2.42% |
CYP1A2-inhibitor: | 0.321 | CYP1A2-substrate: | 0.361 |
CYP2C19-inhibitor: | 0.256 | CYP2C19-substrate: | 0.806 |
CYP2C9-inhibitor: | 0.348 | CYP2C9-substrate: | 0.749 |
CYP2D6-inhibitor: | 0.896 | CYP2D6-substrate: | 0.616 |
CYP3A4-inhibitor: | 0.942 | CYP3A4-substrate: | 0.612 |
Clearance (CL): | 7.235 | Half-life (T1/2): | 0.177 |
hERG Blockers: | 0.644 | Human Hepatotoxicity (H-HT): | 0.311 |
Drug-inuced Liver Injury (DILI): | 0.03 | AMES Toxicity: | 0.004 |
Rat Oral Acute Toxicity: | 0.917 | Maximum Recommended Daily Dose: | 0.943 |
Skin Sensitization: | 0.691 | Carcinogencity: | 0.81 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.034 |
Respiratory Toxicity: | 0.978 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001931 | 0.717 | D0H4JM | 0.288 | ||||
ENC004710 | 0.667 | D0Q6NZ | 0.256 | ||||
ENC000857 | 0.632 | D08QKJ | 0.252 | ||||
ENC003933 | 0.607 | D01JGV | 0.248 | ||||
ENC003874 | 0.589 | D0U7GP | 0.248 | ||||
ENC005883 | 0.583 | D04VIS | 0.242 | ||||
ENC003172 | 0.573 | D0H2JP | 0.241 | ||||
ENC005989 | 0.573 | D06AWE | 0.241 | ||||
ENC005406 | 0.573 | D02VPX | 0.239 | ||||
ENC003932 | 0.565 | D04RLY | 0.237 |